{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03255434\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LEANOX","nct_id":"NCT03255434","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=leanox-nct03255434. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LEANOX","arms":[{"description":"Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²","label":"Folfox 4","type":"ACTIVE_COMPARATOR"},{"description":"Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)","label":"Folfox 4 LBM","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-07-31","type":"ESTIMATED"},"conditions":["Stage III Colon Cancer"],"enrollment":{"count":160,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin LBM","otherNames":["Oxaliplatin"],"type":"DRUG"}],"last_update":"2025-02-13","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","official_title":"LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-07-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Evaluation of neurotoxicity associated with Oxaliplatin","timeFrame":"through study completion, an average of 5 years"}],"references":[{"citation":"Assenat E, Ben Abdelghani M, Gourgou S, Perrier H, Akouz FK, Desgrippes R, Galais MP, Janiszewski C, Mazard T, Rinaldi Y, Lepage C, Tetreau R, Senesse P. Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. J Clin Oncol. 2025 Aug 10;43(23):2616-2627. doi: 10.1200/JCO-24-02754. Epub 2025 Jun 20.","pmid":"40540704","type":"DERIVED"}],"start_date":{"date":"2017-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03255434"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/leanox-nct03255434"}